Abstract
Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patients with BCG-unresponsive high-risk NMIBC. To describe the rationale and design for the randomized, comparator-controlled Phase III KEYNOTE-676 study, which will evaluate the efficacy and safety of pembrolizumab in combination with BCG in patients with persistent/recurrent high-risk NMIBC after BCG induction therapy. Trial registration number: NCT0371103.
Original language | English (US) |
---|---|
Pages (from-to) | 507-516 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 16 |
Issue number | 10 |
DOIs | |
State | Published - Apr 2020 |
Keywords
- Bacillus Calmette-Guérin
- bladder cancer
- immunotherapy
- nonmuscle-invasive bladder cancer
- pembrolizumab
- programmed death 1
- programmed death ligand 1
ASJC Scopus subject areas
- Oncology
- Cancer Research